US 11,970,534 B2
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
Stephen Sunghan Yoo, Centreville, VA (US); Michael Joseph Surace, Germantown, MD (US); Steven Hsesheng Lin, Pearland, TX (US); and Amrish Sharma, Houston, TX (US)
Assigned to STCUBE & CO., INC., Seoul (KR); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed by STCUBE & CO., INC., Seoul (KR); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Nov. 24, 2020, as Appl. No. 17/103,308.
Application 17/103,308 is a division of application No. 15/781,071, granted, now 10,875,920, previously published as PCT/US2016/064436, filed on Dec. 1, 2016.
Claims priority of provisional application 62/262,309, filed on Dec. 2, 2015.
Prior Publication US 2021/0147537 A1, May 20, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/395 (2013.01); C07K 2317/34 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
 
1. A method of inhibiting the proliferation of cancer cells expressing BTN1A1 comprising contacting the cells with an effective amount of a molecule, wherein the molecule comprises an antigen binding fragment that immunospecifically binds to BTN1A1, wherein said antigen binding fragment comprises:
(i) (a) a heavy chain variable region (VH) comprising a VH complementarity-determining region (CDR) 1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:3; and
(b) a light chain variable region (V) comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:5; or
(ii) (a) a VH comprising:
(1) a VH CDR1 having the amino acid sequence of SEQ ID NO:7;
(2) a VH CDR2 having the amino acid sequence of SEQ ID NO:8; and
(3) a VH CDR3 having the amino acid sequence of SEQ ID NO:9; and
(b) a VL comprising:
(1) a VL CDR1 having the amino acid sequence of SEQ ID NO:19;
(2) a VL CDR2 having the amino acid sequence of SEQ ID NO:20; and
(3) a VL CDR3 having the amino acid sequence of SEQ ID NO:21;
or
(iii) (a) a VH comprising:
(1) a VH CDR1 having the amino acid sequence of SEQ ID NO:10;
(2) a VH CDR2 having the amino acid sequence of SEQ ID NO:11; and
(3) a VH CDR3 having the amino acid sequence of SEQ ID NO:12; and
(b) a VL comprising:
(1) a VL CDR1 having the amino acid sequence of SEQ ID NO:22;
(2) a VL CDR2 having the amino acid sequence of SEQ ID NO:23; and
(3) a VL CDR3 having the amino acid sequence of SEQ ID NO:24;
or
(iv) (a) a VH comprising:
(1) a VH CDR1 having the amino acid sequence of SEQ ID NO:13;
(2) a VH CDR2 having the amino acid sequence of SEQ ID NO:14; and
(3) a VH CDR3 having the amino acid sequence of SEQ ID NO:15; and
(b) a VL comprising:
(1) a VL CDR1 having the amino acid sequence of SEQ ID NO:25;
(2) a VL CDR2 having the amino acid sequence of SEQ ID NO:26; and
(3) a VL CDR3 having the amino acid sequence of SEQ ID NO:27;
or
(v) (a) a VH comprising:
(1) a VH CDR1 having the amino acid sequence of SEQ ID NO:16;
(2) a VH CDR2 having the amino acid sequence of SEQ ID NO:17; and
(3) a VH CDR3 having the amino acid sequence of SEQ ID NO:18; and
(b) a VL comprising:
(1) a VL CDR1 having the amino acid sequence of SEQ ID NO:28;
(2) a VL CDR2 having the amino acid sequence of SEQ ID NO:29; and
(3) a VL CDR3 having the amino acid sequence of SEQ ID NO:30.